الفهرس 
List of contents
High-mobility group box 1 and systemic lupus erythematosusOnly 14 pages are availabe for public view
 |  | from | 147 |  |  |
| | | from | 147 | | |
Abstract
SLE is a systemic inflammatory disease. Clinically the distinction between ongoing inflammations attributed to SLE and organ damage due to medication or co-morbidities remains challenging. Additionally, SLE is a heterogeneous disease where the various disease phenotypes complicate the search for biomarkers that adequately reflect disease activity and/or signs of increasing organ damage.The aim of the current study is to estimate prevalence of anti-HMGB1 in patients with systemic lupus erythematosus and its correlation to disease activity. The study included two groups the first group included 45 SLE patients the second group formed of apparently health controls. All the patients and controls were subjected to thorough clinical and laboratory investigations. Disease activity was calculated for all patients and its relation to anti-HMGB1 antibodies.The results of the current study revealed that:There was no statistical significant difference in the mean age or sex between the SLE patients and healthy controls. There was a statistical significant difference regarding patients serum concentrations of anti-HMGB1 antibodies and its concentrations in controls sera. A significant correlation was found between anti-HMGB1 antibodies in patients’ sera with SLEDAI score.There was a significant statistical association of anti-HMGB1 antibodies and fever.